JPMorgan Chase & Co. 13D and 13G filings for Atara Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-12-07 2:45 pm Sale |
2023-11-30 | 13G | Atara Biotherapeutics, Inc. ATRA |
J P MORGAN CHASE & CO JPM |
88,277 2.100% |
-212,146 (-70.62%) |
Filing |
| 2023-01-18 1:30 pm Purchase |
2022-12-30 | 13G | Atara Biotherapeutics, Inc. ATRA |
J P MORGAN CHASE & CO JPM |
300,423 7.900% |
3,387 (+1.14%) |
Filing |
| 2022-01-07 3:41 pm Purchase |
2021-12-31 | 13G | Atara Biotherapeutics, Inc. ATRA |
J P MORGAN CHASE & CO JPM |
297,036 8.300% |
55,896 (+23.18%) |
Filing |
| 2021-01-08 11:43 am Purchase |
2020-12-31 | 13G | Atara Biotherapeutics, Inc. ATRA |
J P MORGAN CHASE & CO JPM |
241,140 7.300% |
241,140 (New Position) |
Filing |